

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-87. (Cancelled)

88. (New) A method to select a lung cancer patient who is predicted to benefit from therapeutic administration of from therapeutic administration of an EGFR inhibitor selected from the group consisting of gefitinib and erlotinib comprising:

a) detecting the level of E-cadherin polynucleotides in a sample of tumor cells from said patient;

b) comparing said level to a level of E-cadherin polynucleotides in a sample of tumor cells from a subject having lung cancer that is resistant to gefitinib; and,

c) selecting the patient as being predicted to benefit from therapeutic administration of an EGFR inhibitor selected from the group consisting of gefitinib and erlotinib, if the level of E-cadherin polynucleotides in the sample of tumor cells from said patient is higher than the level of E-cadherin polynucleotides in the sample of tumor cells from the subject that is resistant to gefitinib.

89. (New) The method of Claim 82, comprising detecting expression of the E-cadherin polynucleotide represented by SEQ ID NO:3.

90. (New) The method of Claim 82, wherein the EGFR inhibitor is gefitinib.

91. (New) The method of Claim 82, wherein the EGFR inhibitor is erlotinib.